Summary
The Food and Drug Administration (FDA) will meet in July to discuss easing rules on several peptide therapies that are not approved yet. Health Secretary Robert F. Kennedy Jr. supports relaxing restrictions on these peptides, which are popular online but lack strong scientific proof of safety and effectiveness.
Key Facts
- The FDA plans a July meeting to review seven peptides for possible safe use by compounding pharmacies.
- Peptides are small proteins that can affect growth and healing in the body.
- Many peptides promoted online, like BPC-157, claim to help with muscle growth and injury but have little scientific testing.
- Secretary Robert F. Kennedy Jr. has publicly endorsed peptides and said he uses them for injuries.
- The FDA intends to remove these peptides from a high-risk list, potentially making them easier to get.
- Critics warn that selling peptides without full drug approval could weaken drug safety checks.
- Under President Joe Biden, the FDA had placed many peptides on a restricted list, citing safety concerns.
- The FDA advisory panel reviewing this issue currently has several vacant positions, which Kennedy may fill before the meeting.
